Tim Funnell is a seasoned professional in the biotechnology and venture capital sectors, currently serving as a Partner at Monograph Capital since June 2021, focusing on building transformative biotech companies. As the Chief Operating Officer and founding team member of Elevara Medicines since March 2025, Tim Funnell contributes to the development of innovative therapies for rheumatoid arthritis. In addition to roles as Investor Director at Ouro Medicines, Maxion Therapeutics, and AviadoBio, Tim Funnell holds an Executive Director position at Ascend Advanced Therapies, where leadership is dedicated to expanding business capabilities and supporting gene and cell therapy programs. Previously, Tim Funnell played a pivotal role as VP of Operations at MiroBio Ltd, contributing to its acquisition by Gilead for $405 million, and served as an Entrepreneur In Residence at Oxford Science Enterprises. Tim Funnell's academic credentials include a DPhil in Pharmacology from the University of Oxford and an MA in Natural Sciences from the University of Cambridge.
This person is not in the org chart
This person is not in any teams
This person is not in any offices